Comprehensive Segmental Revision System
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03270982|
Recruitment Status : Recruiting
First Posted : September 1, 2017
Last Update Posted : July 20, 2021
|Condition or disease||Intervention/treatment|
|Degenerative Disease Oncology Revision Surgery Trauma Rheumatoid Arthritis||Device: Comprehensive SRS Replacement|
The Purpose of this multi centre clinical data evaluation is to document the performance and clinical outcomes of the Comprehensive Segmental revision System. The data gathered will be collated and used to provide feedback to designing engineers, support marketing efforts, answer potential questions from reimbursement agencies, and will serve as part of Zimmer Biomets Post Market Surveillance.
The Comprehensive Segmental Revision System consists of a proximal humeral replacement system (shoulder prosthesis), a distal humeral replacement system (elbow prosthesis) and of a total humeral replacement system (shoulder and elbow prosthesis connected by a humeral coupler).
Patient outcomes will be measured by using measurement tools that have been extensively used and referred to in the literature. Specifically, the quickDASH will be used for all cases enrolled in the study. In addition, the Constant and Murley Score may be used for shoulder applications, the Liverpool Elbow Score may be used for elbow applications and the MSTS Score may be used for tumor cases.
The study population will be compromised of males and females that are eligible according to the inclusion/exclusion criteria. The study will last for at least five (5) years from the time of surgery.
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Comprehensive Segmental Revision System|
|Actual Study Start Date :||April 2016|
|Estimated Primary Completion Date :||April 2026|
|Estimated Study Completion Date :||December 2030|
|Comprehensive SRS Replacement||
Device: Comprehensive SRS Replacement
This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
- Implant survivorship assessed according to the implant revisions [ Time Frame: 10 years ]Implant survivorship assessed counting the number of implant revisions
- Clinical patient outcome measure: QuickDASH [ Time Frame: Pre-operative and at 6 months, 1 year, 3 years and 5 years post-operative ]The QuickDASH score will be used to measure physical function and symptoms of the upper limb in patients to be treated/treated with the Comprehensive SRS products.
- Clinical patient outcome measure: Constant-Murley Score [ Time Frame: Pre-operative and at 6 months, 1 year, 3 years and 5 years post-operative ]The Constant-Murley score may be used to define the level of pain and the ability to carry out the normal daily activities in patients to be treated/treated with the Comprehensive SRS products. The score consists of objective (ROM, strength) and subjective (pain, functional assessment) variables.
- Clinical patient outcome measure: Liverpool Elbow Score [ Time Frame: Pre-operative and at 6 months, 1 year, 3 years and 5 years post-operative ]The Liverpool Elbow Score may be used to define elbow condition, function and pain in patients to be treated/treated with the Comprehensive SRS products.The score consists of two components: one patient-rated part and another part that can be measured objectively.
- Clinical patient outcome measure: Musculoskeletal Tumour Society Scoring System (MSTS) [ Time Frame: 6 months, 1 year, 3 years and 5 years post-operative ]The MSTS Score may be used as a functional measure for patients with sarcoma involving the upper limb. The score includes 6 measures (pain, function, emotional acceptance, hand position, manual dexterity, lifting ability) each measure with a maximum of 5 points. The maximum overall score is 30 points. The score is designed to be used after the procedure and is therefore only collected post-operatively.
- Safety is assessed according to the number of complications [ Time Frame: 10 years ]Safety is assessed according to the number of complications which are collected via adverse event forms
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03270982
|Contact: Oliver Schaetti, PhD||+41 58 854 89 email@example.com|
|Contact: Paola Vivoda||+41 58 854 82 firstname.lastname@example.org|
|Canada, Nova Scotia|
|Nova Scotia Health Authority||Recruiting|
|Halifax, Nova Scotia, Canada, B3H-1796|
|Contact: Kelly Trask|
|Principal Investigator: Michael Biddulph|
|Department of Orthopedic Surgery, Rigshospitalet University of Copenhagen||Recruiting|
|Contact: Michael Mork Petersen, MD 004522400743 email@example.com|
|Royal Gwent Hospital||Recruiting|
|Newport, Wales, United Kingdom, NP20 2UB|
|Contact: Huw Pullen, MD +441633 234839 pullenhuw@Hotmail.com|
|University of Liverpool||Recruiting|
|Liverpool, United Kingdom|
|Contact: Mohamed Galhoum, MD +447920405089 firstname.lastname@example.org|
|Study Chair:||Oliver Schaetti, PhD||Zimmer Biomet, Jr. Clinical Project Lead|